Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction
- 3.1k Downloads
Background Clinical trials comparing incretin-based therapies—glucagon-like peptide-1 receptor agonists (exenatide—twice daily and once weekly—and once-daily liraglutide) and dipeptidyl peptidase-4 inhibitors (vildagliptin, sitagliptin, saxagliptin and linagliptin)—with placebo and oral antidiabetic drugs show that these therapies effectively control glycaemia, with low risk of hypoglycaemia. Glucagon-like peptide-1 receptor agonists are associated with weight loss and reductions in systolic blood pressure, while dipeptidyl peptidase-4 inhibitors are weight-neutral. Based on this, the National Institute for Health and Clinical Excellence recommends using these agents in patients with type 2 diabetes for whom excess weight and/or hypoglycaemia are problematic. Aim of the review This review aims to help decision making when selecting and using incretin-based therapies in type 2 diabetes. Methods A search or MEDLINE and Cochrane clinical trials databases, limited to clinical trials in humans, was performed using the search criteria ‘exenatide or liraglutide or vildagliptin or sitagliptin, or saxagliptin or linagliptin’. Abstracts presented at recent American Diabetes Association and European Association for the Study of Diabetes meetings were also searched. Eighteen clinical trials directly comparing incretin-based therapies were identified. Results Glucagon-like peptide-1 receptor agonists achieved significantly greater reductions in glycated hemoglobin and weight than dipeptidyl peptidase-4 inhibitors, which have a neutral effect on weight. Between-treatment differences were clinically important. Gastrointestinal side effects were more frequent with glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors. Comparisons between glucagon-like peptide-1 receptor agonists and between dipeptidyl peptidase-4 inhibitors showed that differences within the available agents in the two sub-classes are small. Greater treatment satisfaction was reported with glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors. Conclusion Glucagon-like peptide-1 receptor agonists achieve greater glycated hemoglobin reductions than dipeptidyl peptidase-4 inhibitors, with concomitant weight loss. Probably due to the greater efficacy of glucagon-like peptide-1 receptor agonists, patient satisfaction is greater with these agents compared with dipeptidyl peptidase-4 inhibitors despite injectable versus oral administration and more frequent gastrointestinal side effects with the agonists.
KeywordsClinical guidelines DPP-4 inhibitors GLP-1 receptor agonists Review Type 2 diabetes
The author would like to thank Watermeadow Medical, UK, for assistance in preparing a draft version of this manuscript.
Funding for editorial and writing support was provided by Novo Nordisk.
Conflicts of interest
SR declares that preparation of the manuscript was funded by Novo Nordisk UK. This manuscript details the views of the author and not necessarily the views of Barndoc Healthcare Ltd.
- 1.The International Diabetes Federation. IDF Diabetes Atlas. 4th ed. 2009. Available from: http://www.diabetesatlas.org/content/international-diabetes-federation. Accessed 9 May 2012.
- 2.Diabetes UK. Publications, reports and resources: Reports and statistics (Diabetes prevalence 2010). 2010. Available from: http://www.diabetes.org.uk/Professionals/Publications-reports-and-resources/Reports-statistics-and-case-studies/Reports/Diabetes-prevalence-2010. Accessed 9 May 2011.
- 4.Bergenstal RM, Kendall DM. Management of type 2 diabetes: a systematic approach to meeting the standards of care: oral agents, insulin, and management of complications. In: Degroot LJ, Jameson JL, editors. Endocrinology. Philadelphia, PA: Saunders; 2001. p. 821–35.Google Scholar
- 6.Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev. 1999;7(3):139–53.Google Scholar
- 11.[No authors listed]. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–65.Google Scholar
- 31.Amylin Pharmaceuticals, Inc. Byetta 5 μg and 10 μg for injection: summary of product characteristics. 2011. Available from: http://www.medicines.org.uk/emc/medicine/19257. Accessed 9 May 2012.
- 32.Novo Nordisk Limited. Victoza 6 mg/mL solution for injection in pre-filled pen: summary of product characteristics. 2012. Available from: http://www.medicines.org.uk/emc/medicine/21986/SPC/. Accessed 26 April 2012.
- 33.Novartis Pharmaceuticals UK Ltd. Galvus 50 mg tablets: summary of product characteristics. 2011. Available from: http://www.medicines.org.uk/emc/history/20734/SPC/Galvus. Accessed 9 May 2012.
- 34.Merck Sharp & Dohme Ltd. Januvia 100 mg film-coated tablets: summary of product characteristics. 2011. Available from: http://www.medicines.org.uk/EMC/medicine/23111/SPC/Janumet+50+mg+1000+mg+film-coated+tablets. Accessed 9 May 2012.
- 35.Bristol-Myers Squibb-AstraZeneca EEIG. Onglyza 5 mg film-coated tablets: summary of product characteristics. 2012. Available from: http://www.medicines.org.uk/EMC/medicine/22315/SPC/Onglyza+5mg+film-coated+tablets. Accessed 9 May 2012.
- 36.Eli Lilly and Company Limited. Bydureon 2 mg powder and solvent for prolonged-release suspension for injection: summary of product characteristics. 2011. Available from: http://www.medicines.org.uk/EMC/medicine/24665/SPC/BYDUREON+2+mg+powder+and+solvent+for+prolonged-release+suspension+for+injection/. Accessed 9 May 2012.
- 37.Boehringer Ingelheim Limited. Trajenta 5 mg film-coated tablets: summary of product characteristics. 2011. Available from: http://www.medicines.org.uk/emc/medicine/25000/SPC/trajenta%205%20mg%20film-coated%20tablets/. Accessed 9 May 2012.
- 38.Scottish Intercollegiate Guidelines Network. Management of diabetes: a national clinical guideline. Clinical guideline 116. 2010. Available from: http://www.sign.ac.uk/pdf/sign116.pdf. Accessed 9 May 2012.
- 39.National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. 2009. Available from: http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf. Accessed 9 May 2012.
- 40.National Institute for Health and Clinical Excellence. NICE technology appraisal guidance TA203: liraglutide for the treatment of type 2 diabetes mellitus. 2010. Available from: http://www.nice.org.uk/nicemedia/live/13248/51259/51259.pdf. Accessed 9 May 2012.
- 41.National Institute for Health and Clinical Excellence. NICE technology appraisal guidance TA248: exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes. 2012. Available from: http://www.nice.org.uk/nicemedia/live/13670/58205/58205.pdf. Accessed 20 April 2012.
- 43.Rosenstock J, Gumprecht J, Szyprowska E, Bednarczyk-Kaluzny M, Zychma M, During M, et al. Pharmacokinetics of liraglutide vs. exenatide in type 2 diabetes: sustained vs. fluctuating concentrations over 24 hours. Diabetes. 2009;58(Suppl. 1):A150.Google Scholar
- 45.Watson E, Jonker DM, Jacobsen LV, Ingwersen SH. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. J Clin Pharmacol. 2010;50(8):886–94.PubMedCrossRefGoogle Scholar
- 48.Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S. et al; 1860-LIRA-DPP-4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397–407.PubMedCrossRefGoogle Scholar
- 50.Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M. et al; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252–8.PubMedCrossRefGoogle Scholar
- 52.Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse JB. Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. Diabet Med. 2011;28(6):715–23.PubMedCrossRefGoogle Scholar
- 53.Buse JB, Nauck MA, Forst T, Sheu WH, Shenouda SK, Heilmann CR, Hoogwerf BJ, et al. Exenatide once weekly versus liraglutide once daily patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2012; doi: 10.1016/S0140-6736(12)61267-7.
- 54.Eli Lilly. Press release—DURATION-6 top-line study results announed. 2011. Available from: https://investor.lilly.com/releasedetail2.cfm?ReleaseID=554248. Accessed 12 Feb 2012.
- 55.Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447–56.PubMedCrossRefGoogle Scholar
- 60.Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431–9.PubMedCrossRefGoogle Scholar
- 61.Best JH, Rubin RR, Peyrot M, Li Y, Yan P, Malloy J, et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care. 2011;34(2):314–9.PubMedCrossRefGoogle Scholar
- 62.Scheen AJ, Charpentier G, Östgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26:540–9.PubMedCrossRefGoogle Scholar
- 66.Bergenstal R, Daniels G, Mann J, Nissen S, Pocock S, Zinman B, et al. Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER™) trial: rationale and study design. Diabetes. 2011;60(Suppl. 1):A612–3.Google Scholar
- 67.Merck & Co. TECOS: A randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with sitagliptin in patients with type 2 diabetes mellitus and inadequate glycemic control (ClinicalTrials.gov identifier: NCT00790205). 2008. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00790205?term=TECOS&rank=1. Accessed 9 May 2012.
- 68.AstraZeneca. Does saxagliptin reduce the risk of cardiovascular events when used alone or added to other diabetes medications (SAVOR- TIMI 53). 2010. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01107886?term=saxagliptin+cardiovascular&rank=1. Accessed 9 May 2012.
- 69.Amylin Pharmaceuticals, Inc. Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. 2010. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01144338?term=EXSCEL&rank=1. Accessed 9 May 2012.
- 70.Boehringer Ingelheim Pharmaceuticals. A multicentre, international, randomised, parallel group, double blind study to evaluate cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk (CAROLINA). 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01243424?term=CAROLINA+linagliptin&rank=1. Accessed 9 May 2012.
- 74.UK Department of Health. Department of Health: quality and outcomes framework. Available from URL: http://www.dh.gov.uk/en/Healthcare/Primarycare/PMC/Quality/OutcomesFramework/index.htm. Accessed 9 May 2012.